MAX Chat
Share chart Recursion Pharmaceuticals, Inc.
Extended chart
Simple chart
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. работает как биотехнологическая компания на клинической стадии, расшифровывающая биологию путем интеграции технологических инноваций в области биологии, химии, автоматизации, науки о данных и инженерии для индустриализации открытия лекарств. В нем есть четыре кандидата на клинические препараты, предназначенные для лечения редких моногенных заболеваний; и 33 дополнительных программы на разных стадиях доклинической разработки. Recursion Pharmaceuticals, Inc. имеет стратегические соглашения с Bayer; Государственный инновационный фонд Огайо; Chromaderm, Inc .; и Takeda Pharmaceutical Company Limited. Компания была основана в 2013 году и базируется в Солт-Лейк-Сити, штат Юта.
Main settings
IPO date
2021-04-16
ISIN
US75629V1044
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 31.5 | 1 |
| P/BV | 1.79 | 8 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -44.11 | 0 |
| ROE | -61.89 | 0 |
| ROIC | -127.47 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.2542 | 10 |
| Debt/Ratio | 0.0749 | 10 |
| Debt/Equity | 0.3999 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 1370.98 | 10 |
| Yield Ebitda, % | 425.49 | 10 |
| Yield EPS, % | 119.6 | 10 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 5.17 $ | 0 $ | 0 $ | -1.45 % | 0 % | 0 % |
| Week | 4.57 $ | 0 $ | 0 $ | +11.49 % | 0 % | 0 % |
| Month | 4.15 $ | 0 $ | 0 $ | +22.92 % | 0 % | 0 % |
| Three month | 4.65 $ | 4.08 $ | 5.84 $ | +9.57 % | 0 % | 0 % |
| Half a year | 7.61 $ | 3.97 $ | 10.87 $ | -33.05 % | 0 % | 0 % |
| Year | 7.61 $ | 3.97 $ | 10.87 $ | -33.05 % | 0 % | 0 % |
| 3 years | 10.99 $ | 3.97 $ | 15.86 $ | -53.64 % | 0 % | 0 % |
| 5 years | 3.97 $ | 3.97 $ | 41.33 $ | +128.34 % | 0 % | 0 % |
| 10 years | 3.97 $ | 3.97 $ | 41.33 $ | +128.34 % | 0 % | 0 % |
| Year to date | 6.53 $ | 3.97 $ | 10.87 $ | -21.98 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Future Tech ETF | 0.18148 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 0.18148 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Growth ETF | 0.06084 | 570.49 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.03054 | 301.34 | 0.25 |
| 0.11 | 336.85 | 0.25 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Tina Marriott Larson | COO & President | 612.69k | 1975 (50 years) |
| Dr. Blake C. Borgeson Ph.D. | Co-Founder & Director | 40k | 1982 (43 years) |
| Dr. Michael Secora Ph.D. | Chief Financial Officer | 524.19k | 1983 (42 years) |
| Mr. Benjamin Mabey M.S. | Chief Technology Officer | N/A | 1983 (42 years) |
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, CEO & Director | 695.18k | 1983 (42 years) |
| Kevin Leggat | Vice President of Finance & Accounting | N/A | |
| Mr. Jared Allenbach | Senior Director of Investor Relations | N/A | |
| Mr. Ryan Kelly | Chief Communications Officer | N/A | |
| Mr. Nathan Hatfield | Chief Legal Officer & General Counsel | N/A | |
| Dr. David J. Mauro M.D., Ph.D. | Chief Medical Officer | 1965 (60 years) |
About company
Address: United States, Salt Lake City, 41 South Rio Grande Street - Open in google maps, Open in yandex maps
Website: http://www.recursion.com
Website: http://www.recursion.com
